Featuring

Jeffrey Tyner

Professor, Oregon Health & Science University

Principle Investigator, ARTNet AML U54 Center

Dr. Tyner is a leading researcher in cancer biology and therapeutic resistance, with a focus on acute myeloid leukemia (AML), functional precision oncology, and mechanisms of acquired resistance to targeted therapies.

Hosted by

David Goodrich

Professor, Roswell Park Comprehensive Cancer Center

ARTNet Coordinating and Data Management Center

Dr. Goodrich leads discussions exploring the science, collaboration, and translational impact of cancer resistance research across the ARTNet Consortium.

Episode Summary

The conversation explores the complexity of acquired resistance in cancer therapy, emphasizing the role of cell state and cellular plasticity in driving resistance mechanisms. Dr. Tyner discusses the challenges of studying dynamic resistance processes, the promise of targeting cell state plasticity to overcome therapeutic failure, and how resistance trajectories evolve over time.

The discussion also highlights the importance of identifying the optimal window for intervention and the growing role of collaborative science within the ARTNet Consortium in advancing cancer resistance research. Despite the complexity of the problem, the episode reflects a strong sense of optimism about the future of precision oncology and translational cancer research.

Key Takeaways

• Acquired resistance is a dynamic and evolving process in cancer therapy
• Cell state plasticity plays a central role in therapeutic resistance
• Resistance mechanisms can differ across patients and tumor contexts
• Understanding resistance trajectories may reveal new therapeutic opportunities
• Collaborative research and data sharing are essential for advancing precision oncology

Chapters

• 00:00 Introduction to ARTNet Consortium
• 05:15 From Targeted Therapy to Tumor Complexity
• 10:15 Understanding Acquired Resistance and Tumor Evolution
• 19:50 Cell State Plasticity and Therapeutic Resistance
• 24:05 Resistance Trajectories and Future Treatment Strategies
• 29:00 The Future of Precision Oncology and the Role of ARTNet